Blue Lagoon Resources Inc.
STRONG MARKET DEMAND LEADS TO 48% OVER SUBSCRIPTION
VANCOUVER, BC / ACCESSWIRE / July 15, 2021 / Blue Lagoon Resources Inc. (the "Company") (CSE:BLLG) (FSE:7BL) (OTCQB:BLAGF)is pleased to announce that further to its news release dated July 8, 2021, the Company has closed a non-brokered flow through and non-flow through financing for proceeds of $8,130,908.31. Crescat Capital LLC ("Crescat") was the lead order and made a strategic investment of $1.5 Million, representing more than 18% of the total financing. In addition, Crescat requested and secured, participation rights that provide for an option to participate in all future financings.
"We are very pleased with the strong market demand that came from sophisticated investors whose desire to participate in our company lead to a strong closing of this financing which was 48% over subscribed," said Rana Vig, President & CEO of Blue Lagoon Resources. "With this capital raise, an existing healthy treasury, no debt, and nearly $4 million in-the-money warrants, the Company will be very well funded to execute on an aggressive drill program at Dome Mountain this year, one that could result in the recognition of Dome Mountain as a potentially large, high-grade gold system," he added.
FINANCING DETAILS
The private placement (the "Private Placement") consisted of 4,761,154 charity flow-through units ("Charity Units") at a price of $0. 7425 per Unit, 609,758 regular flow-through units (the "FT Units") at a price of $0.82 per unit, and 7,446,818 non-flow-through units (the "NFT Units") at a price of $0.55 per unit, for aggregate gross proceeds to the Company of $8,130,908.31. Each of the units is comprised of one common share of the Company and one-half of one common share purchase warrant. Each whole warrant is exercisable into one common share of the Company at an exercise price of $0.75 per share in the case of the Charity Units and the NFT Units, or $1.10 per share in the case of the FT Units, until July 15, 2023.
Proceeds from the sale of the Charity Units and FT Units will be used for exploration activities in accordance with flow-through tax rules. Proceeds from the sale of the NFT Units will be used for exploration as well as for general working capital purposes.
The Company paid finders' fees in cash in the aggregate amount of $171,863.08, equal to 7% of the gross proceeds from the sale of Units to certain third parties sourced by the finders and issued an aggregate of 202,199 finders' warrants to purchase that number of common shares of the Company, equal to 7% of the number of Units sold to those third parties. The finder's warrants may be exercised to acquire common shares of the Company at a price of $0.75 per common share until July 15, 2023 and are otherwise on the same terms as the Private Placement warrants. 42,683 finder's warrants are exercisable at a price of $1.10 per common share until July 15, 2023.
The securities issued pursuant to the Private Placement are subject to a statutory four month hold period ending on November 16, 2021 in accordance with applicable securities laws.
OPTION GRANT
The Company has granted a total of 960,000 stock options to directors, employees, and consultants of the Company in accordance with the Company's stock option plan. Each option is exercisable into one common share of the Company at a price of $0.70 per share. The options vested on grant and will expire on July 15, 2026. The stock options are subject to the acceptance of the Canadian Securities Exchange (CSE).
About Crescat Capital LLC
Crescat is a global macro asset management firm headquartered in Denver, Colorado. Crescat's mission is to grow and protect wealth over the long term by deploying tactical investment themes based on proprietary value-driven equity and macro models. Crescat's goal is industry leading absolute and risk-adjusted returns over complete business cycles with low correlation to common benchmarks. Crescat's investment process involves a mix of asset classes and strategies to assist with each client's unique needs and objectives and includes Global Macro, Long/Short, Large Cap and Precious Metals funds.
Crescat is advised by its technical consultant Dr. Quinton Hennigh on investments in gold and silver resource companies. Dr. Hennigh became an economic geologist after obtaining his PhD in Geology/Geochemistry from the Colorado School of Mines. He has more than 30 years of exploration experience with major gold mining firms that include Homestake Mining, Newcrest Mining and Newmont Mining. Recently, Dr. Hennigh founded Novo Resources Corp (TSXV: NVO) and serving as Chairman. Among his notable project involvements are First Mining Gold's Springpole gold deposit in Ontario, Kirkland Lake Gold's acquisition of the Fosterville gold mine in Australia, the Rattlesnake Hills gold deposit in Wyoming, and Lion One's Tuvatu gold project on Fiji, among many others.
For further information, please contact:
Rana Vig
President and Chief Executive Officer Telephone: 604-218-4766
Email: rana@ranavig.com
The CSE has not reviewed and does not accept responsibility for the adequacyor accuracy of this release. The securities referenced in this news release have not and will not be registered under the U.S. Securities Act of 1933, as amended and may not be offered or sold in the United States absent registration or an applicable exemption from registration requirements. This news release does not constitute an offer to sell or the solicitation of any offer to buy nor will there be any sale of these securities in any province, state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such province, state or jurisdiction.
This release includes certain statements that may be deemed "forward-looking statements". All statements in this release, other than statements of historical facts, that address events or developments that Blue Lagoon Resources Inc. (the "Company") expects to occur, are forward-looking statements. Forward-looking statements are statements that are not historical facts and are generally, but not always, identified by the words "expects", "plans", "anticipates", "believes", "intends", "estimates", "projects", "potential" and similar expressions, or that events or conditions "will", "would", "may", "could" or "should" occur. Although the Company believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results may differ materially from those in the forward-looking statements. Factors that could cause the actual results to differ materially from those in forward-looking statements include use of proceeds from the Private Placement and acceptance of the stock options by the CSE. Investors are cautioned that any such statements are not guarantees of future performance and actual results or developments may differ materially from those projected in the forward-looking statements. Forward-looking statements are based on the beliefs, estimates and opinions of the Company's management on the date the statements are made. Except as required by applicable securities laws, the Company undertakes no obligation to update these forward-looking statements in the event that management's beliefs, estimates or opinions, or other factors, should change.
SOURCE: Blue Lagoon Resources Inc.
View source version on accesswire.com:
https://www.accesswire.com/655718/Blue-Lagoon-Completes-813-Million-Private-Placement-Lead-by-a-Strategic-Investment-by-Crescat-Capital-for-15-Million
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.
About ACCESS Newswire
Subscribe to releases from ACCESS Newswire
Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESS Newswire
OBI-902 Has Been Granted by US FDA for Orphan Drug Designation for the Treatment of Cholangiocarcinoma17.11.2025 13:00:00 CET | Press release
OBI-902 is the first ADC utilizing OBI's proprietary GlycOBI® glycan-based ADC enabling technology for evaluation of safety and efficacy in patients with Cancer. TAIPEI, TW / ACCESS Newswire / November 17, 2025 / OBI Pharma, a clinical-stage oncology company (4174.TWO) received notification from the US FDA stating that the request for Orphan Drug Designation of OBI-902 TROP2 ADC for the treatment of Cholangiocarcinoma has been granted. OBI-902 is the first OBI-developed ADC that incorporates our proprietary site-specific glycan-conjugated ADC enabling technology. Cholangiocarcinoma is a rare and lethal malignancy with fewer than 50,000 patients in the United States and a 5-year survival rate ranging from 2% and 23% depending on disease stage, histological subtype, and localization 1 . At present, there are no FDA approved ADC therapies for cholangiocarcinoma. To encourage the industry to develop new treatment options for rare diseases, the US FDA grants Orphan Drug Designation to exper
Camino Completes C$5.6 Million Investment with Strategic Investors17.11.2025 12:00:00 CET | Press release
VANCOUVER, BC / ACCESS Newswire / November 17, 2025 / Camino Minerals Corporation (TSXV:COR)(OTC:CAMZF) ("Camino" or the "Company") is pleased to announce the closing of its -brokered private placement (the "Financing") of common shares in the capital of the Company (the "Shares") previously announced in its news release dated November 12, 2025. Under the Financing, the Company issued an aggregate of 15,554,666 Shares at an issue price of $0.36 per Share, for aggregate gross proceeds of C$5,599,680. Participants in the Financing included two new key shareholders, Elemental Royalties (formerly EMX Royalty Corp.) and Continental General Insurance Company, as well as certain insiders of Camino. The gross proceeds of the Financing will be applied towards corporate working capital, legal expenses, engineering studies, project development, and general administrative expenses. The Shares issued pursuant to the Financing are subject to a statutory hold period expiring on March 15, 2026, in acc
GA-ASI Completes Full-Scale Fatigue Test on MQ-9B17.11.2025 03:10:00 CET | Press release
MQ-9B's Third Lifetime Test Completes the FSF Testing Process With a Total of 120,000 Hours DUBAI, UAE / ACCESS Newswire / November 16, 2025 / On October 31, 2025, General Atomics Aeronautical Systems, Inc. (GA-ASI) completed its "third lifetime" of full-scale fatigue (FSF) testing for the MQ-9B Remotely Piloted Aircraft (RPA). Completion of FSF testing for the third and final lifetime includes a total of 120,000 operating hours (40,000+ flight hours per aircraft life) for the RPA and is a key milestone in validating the design of the airframe. The testing verifies the airframe structural integrity in support of certification to the NATO STANAG 4671 standard. The aim of the testing is to identify any potential structural deficiencies ahead of fleet usage and assist in developing inspection and maintenance schedules for the airframe. Test results will be used as documentation for certification and will form the basis for in-service inspections of structural components. "The completion o
GA-ASI and Saab Will Demonstrate AEW&C on MQ-9B in 202617.11.2025 03:05:00 CET | Press release
Two Aerospace Leaders Are Bringing Airborne Early Warning and Control to UAS DUBAI, UAE / ACCESS Newswire / November 16, 2025 / Following their announcement to bring Airborne Early Warning and Control (AEW&C) capability to the world's leading Remotely Piloted Aircraft (RPA) platform, General Atomics Aeronautical Systems, Inc. (GA-ASI) and Saab will now team up to demonstrate the capability in the summer of 2026. The demo will be conducted at GA-ASI's Desert Horizon flight operations facility in Southern California using a GA-ASI MQ-9B equipped with AEW&C supplied by Saab. In partnership with Saab, a leading company in AEW&C systems, GA-ASI is pairing Saab's AEW sensors with the world's longest-range, highest-endurance RPA, the MQ-9B. At sea or over land, adding AEW capabilities on MQ-9B enables persistent air surveillance and enables AEW in areas of the world where it doesn't currently exist or is unaffordable, such as for navy aircraft carriers at sea. "Adding AEW&C to the MQ-9B bring
Doha Tattoo Festival Announced as Ticket Sales Officially Open16.11.2025 12:45:00 CET | Press release
DOHA, QA / ACCESS Newswire / November 16, 2025 / Under the patronage of His Excellency Sheikh Khalifa bin Hamad bin Khalifa Al Thani, Minister of Interior and Commander of the Internal Security Force (Lekhwiya), the first edition of the Doha International Music and Marching Festival (Doha Tattoo) will be held from 16 to 20 December 2025 at Katara Cultural Village. A press conference held at Katara Cultural Village unveiled the line-up of participating bands and ticket details, attended by members of the Doha Tattoo organising committee and partner representatives. The Doha Tattoo will combine precision with musical artistry, showcasing performances by distinguished musical bands from seven countries: the United Kingdom, the United States of America, Turkia, Hashemite Kingdom of Jordan , the Sultanate of Oman, Kazakhstan, and the State of Qatar. The participating line-up includes the Irish Guards and the Royal Air Force Music Services from the United Kingdom, the United States Air Force
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
